Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28629490 | 0.95 | ALDH1A1 (0.50) | PTGS2ALDH1A1CYP3A4MMP12PDCD1 | |
| SCHEMBL4198693 | 0.92 | PTGS2 (0.53) | PTGS2ALDH1A1CYP3A4MMP12PDCD1 | |
| SCHEMBL27679472 | 0.90 | ALDH1A1 (0.54) | ALDH1A1CYP3A4SMN1; SMN2CYP1A2PKM | |
| SCHEMBL11126462 | 0.82 | ALDH1A1 (0.54) | PTGS2ALDH1A1CYP3A4MMP12PDCD1 | |
| SCHEMBL5306707 | 0.80 | CYP2D6 (0.52) | ALDH1A1CYP3A4SMN1; SMN2CYP1A2PKM | |
| SCHEMBL486678 | 0.80 | ALDH1A1 (0.63) | ALDH1A1CYP3A4 | |
| SCHEMBL29194214 | 0.80 | PTGS2 (0.46) | PTGS2ALDH1A1CYP3A4MMP12PDCD1 | |
| SCHEMBL28881766 | 0.79 | ALDH1A1 (0.50) | PTGS2ALDH1A1CYP3A4MMP12PDCD1 | |
| SCHEMBL14798131 | 0.79 | ALDH1A1 (0.61) | ALDH1A1CYP3A4 | |
| SCHEMBL17863579 | 0.78 | ALDH1A1 (0.48) | PTGS2ALDH1A1CYP3A4PGRPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970107-B1 | PHOTOSWITCHABLE HDAC INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2023-11-15 | — | — | EP | claimed |
| EP-4419513-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12384800-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-07-31 | — | — | US | disclosed |
| WO-2025077996-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-04-17 | — | — | WO | disclosed |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| CN-114615999-B | Drug antibody conjugates | 法马马有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2024-03-07 | — | — | US | disclosed |
| US-20140303367-A1 | Methods for Synthesizing Molybdopterin Precursor Z Derivatives | ALEXION PHARMA INTERNATIONAL SÀRL (CH) | 2014-10-09 | — | — | US | disclosed |
| US-8846941-B2 | Functionalized polymers | QUIAPEG AB (SE) | 2014-09-30 | — | — | US | disclosed |
| WO-2014060575-A2 | PROCESS FOR THE ENANTIOSELECTIVE SYNTHESIS OF A TETRAHYDROBENZAZEPINE COMPOUND | MEDICHEM S.A. (ES) | 2014-04-24 | — | — | WO | disclosed |
| US-20140030278-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | QUIAPEG AB (SE) | 2014-01-30 | — | — | US | disclosed |
| EP-2675278-A1 | METHODS FOR SYNTHESIZING MOLYBDOPTERIN PRECURSOR Z DERIVATIVES | Alexion Pharma International SARL (CH) | 2013-12-25 | — | — | EP | disclosed |
| WO-2013186632-A2 | CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS | QUIAPEG AB (SE) | 2013-12-19 | — | — | WO | disclosed |
| EP-2651448-A2 | FUNCTIONALIZED POLYMERS | QuiaPEG AB (SE) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012112922-A1 | METHODS FOR SYNTHESIZING MOLYBDOPTERIN PRECURSOR Z DERIVATIVES | ALEXION PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| US-20120178940-A1 | Functionalized Polymers | QUIAPEG AB (SE) | 2012-07-12 | — | — | US | disclosed |
| WO-2012080836-A2 | FUNCTIONALIZED POLYMERS | KWIATKOWSKI MAREK (SE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303367-A1 | Methods for Synthesizing Molybdopterin Precursor Z Derivatives | MTHFD2, ADH1B, DPYD | PTGS2 2031/4885ALDH1A1 1289/4885CYP3A4 159/4885 |
| US-12384800-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | PTGS2 394/4885ALDH1A1 144/4885CYP3A4 2078/4885 |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | MCL1, XPOT, GZMB | PTGS2 1461/4885ALDH1A1 318/4885CYP3A4 1651/4885 |
| US-20120178940-A1 | Functionalized Polymers | PARG, PUF60, PCBP1 | PTGS2 1644/4885ALDH1A1 3526/4885CYP3A4 4832/4885 |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | PTGS2 4162/4885ALDH1A1 785/4885CYP3A4 1769/4885 |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | PTGS2 421/4885ALDH1A1 3359/4885CYP3A4 4733/4885 |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | TP53, TOP1, MCL1 | PTGS2 394/4885ALDH1A1 144/4885CYP3A4 2078/4885 |
| US-20140030278-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | PTGS2 421/4885ALDH1A1 3359/4885CYP3A4 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.